Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical trial data translates to real-world practice. Biomarker testing, particularly for ovarian cancer (OC), can be especially promising, helping to identify specific treatments that capitalize on genetic weaknesses of tumors, such as homologous recombination deficiency (HRD) positivity. Members of the multidisciplinary team tasked with care for patients with OC need to know about potential therapy options and determine the value of each for those recently diagnosed or living with recurrent OC. In the fourth activity of this CME Outfitters podcast series on gynecologic cancers, expert faculty will present and discuss the very latest research on biomarker testing, specifically for HRD positivity, for first-line treatment of OC.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/who-what-and-why-of-biomarker-testing-in-ovarian-cancer/
- Start Date: 2024-11-27 06:00:00
- End Date: 2024-11-27 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine, Medical Oncology